Cleaved HMWK Immunoassay With Antibody Capture for Specific Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing assays lack the sensitivity and specificity to effectively distinguish intact high molecular weight kininogen (HMWK) from its cleaved form, which is a biomarker for hereditary angioedema (HAE) and other disorders mediated by plasma kallikrein, hindering accurate monitoring and treatment of these conditions.
Innovation Solution
Development of immunoassays using antibodies that specifically bind cleaved HMWK, immobilized on a support member, and employing optimized conditions such as a 96-well plate and LowCross blocking buffer, enhancing detection sensitivity and specificity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If existing assays are used to detect HMWK, then the assay can be performed with standard methods, but the sensitivity and specificity to distinguish intact HMWK from cleaved HMWK are insufficient
Solution Approach 1:
The assay is divided into distinct functional components: a first antibody specific to cleaved HMWK is immobilized on a support member, while a second antibody conjugated to a label binds to intact HMWK. This segmentation allows each antibody to perform its specific function, enabling differentiation between intact and cleaved forms with high precision without requiring a completely complex new assay system.
Solution Approach 2:
The first antibody specific to cleaved HMWK acts as an intermediary that captures the target analyte on the support member. This intermediary component enables specific binding and differentiation, allowing the assay to achieve high measurement precision while maintaining a manageable level of complexity through the use of well-established immunological techniques.
2Measurement precision
If antibodies specific to cleaved HMWK are immobilized on a support member, then detection sensitivity is enhanced, but the assay procedure becomes more complex
Solution Approach 1:
The first antibody specific to cleaved HMWK is pre-immobilized on the support member before sample addition. This preliminary action prepares the assay system in advance, allowing the capture of cleaved HMWK with high sensitivity while simplifying the overall procedure by eliminating the need for complex real-time differentiation steps during sample analysis.
Solution Approach 2:
Different regions of the assay system are assigned different functions: the support member provides a stable platform for immobilization, the first antibody provides specific capture functionality, and the second antibody provides detection functionality. This local quality differentiation enhances detection sensitivity while organizing the procedure into manageable, functionally-specific steps.
3Measurement precision
If a sandwich ELISA format with two antibodies is used, then specificity for cleaved HMWK is improved, but the time required for the assay increases
Solution Approach 1:
The sandwich ELISA procedure continues through sequential steps without interruption: the first antibody captures cleaved HMWK, followed by addition of the labeled second antibody, then detection. This continuous sequence of useful actions maintains high specificity throughout the assay while minimizing idle time, achieving both precision and reasonable throughput.
Solution Approach 2:
The assay uses two antibodies instead of one, providing more binding events than strictly necessary for simple detection. This partial excess of binding components ensures high specificity for cleaved HMWK while the standardized ELISA protocol keeps the overall time investment manageable through efficient procedural design.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The immunoassays enable high sensitivity and specificity in detecting cleaved HMWK, allowing for accurate monitoring of HAE and other disorders, identifying at-risk patients, and assessing treatment efficacy.
Implementation Method 1
a first agent (e.g., an antibody such as 559B-M004-B04) that specifically binds a cleaved HMWK is attached
Implementation Method 2
contacting the support member obtained in (ii) with a second agent that binds HMWK, wherein the second agent is conjugated to a label
Implementation Method 3
detecting a signal released from the label of the second agent that is bound to the support member
Implementation Method 4
In some instances, step (ii) may be performed in the presence of ZnCl2
Data Source
AI summary
The present disclosure provides immunoassay methods of detecting a cleaved high molecular weight kininogen (HMWK) with high sensitivity and specificity and isolated antibodies that specifically bind cleaved HMWK.